| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 76,408 | 44,857 |
| Share-based compensation | 7,950 | 2,031 |
| Amortization and depreciation | 14,585 | 9,720 |
| Foreign exchange loss (gain) on revaluation of monoplant finance lease liability | -9,318 | -9,265 |
| Net amortization of premiums and discounts on investments | 7,844 | 5,219 |
| Other, net | -4,852 | -4,132 |
| Accounts receivable, net | -5,816 | 3,547 |
| Inventory, net | 5,565 | 7,275 |
| Prepaid expenses and other current assets | -940 | -5,106 |
| Other noncurrent operating assets | -730 | -730 |
| Accounts payable | -2,973 | -1,875 |
| Accrued expenses and other liabilities | -17,777 | -17,136 |
| Deferred revenue | 4,150 | 5,147 |
| Lease liabilities | -600 | -395 |
| Cash flows from operating activities | 89,990 | 45,541 |
| Proceeds from the sale and maturities of investments | 348,785 | 255,285 |
| Purchases of investments | 344,618 | 237,411 |
| Purchases of property, equipment and intangible assets | 180 | 115 |
| Upfront lease payment | 0 | - |
| Cash flows from investing activities | 3,987 | 17,759 |
| Repurchase of common shares | 98,156 | 89,485 |
| Principal portion of finance lease payments | 9,649 | 6,201 |
| Proceeds from issuance of common shares from exercise of stock options and vesting of rsus and performance awards | 12,583 | 10,590 |
| Proceeds from issuance of common shares under espp | 401 | 401 |
| Taxes paid related to net settlement of exercises of stock options and vesting of rsus and performance awards | 9,400 | 9,036 |
| Cash flows from financing activities | -104,221 | -93,731 |
| Net decrease in cash, cash equivalents and restricted cash | -10,244 | -30,431 |
| Cash and cash equivalents at beginning of period | 83,433 | - |
| Cash and cash equivalents at end of period | 73,189 | - |
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)